ASX Announcement

Medibio Limited – 14 OCT 2016



Receipt of \$3,074,224 R & D Tax Incentive Refund

Sydney, Australia – 14 October 2016: Medibio Ltd (MEB or the Company) is pleased to announce that it has today received \$3,074,224 from the Australian Taxation Office under the Research and Development Tax Incentive Program. The cash refund is related to expenditure on eligible Australian and Overseas R&D activities conducted during the 2015/16 financial year.

Further Information: Website: www.medibio.com.au

Medibio Shareholder Enquiries to:

Kris Knauer

CEO and Director Medibio Limited

kris.knauer@medibio.com.au

T: +61 (0)411 885979

Medibio Media Enquiries to:

Peter Taylor

NWR Communications

peter@nwrcommunications.com.au

T: +61 (0)412 036 231

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Melbourne, VIC, Medibio is listed on the Australian Securities Exchange.